Syncom Formulations Share Price | Syncom Formulations Stock Screener
SYNCOMF
Pharmaceuticals
Share Price NSE
₹13.09
▼
-0.06 (-0.46%)
Share Price BSE
₹13.10
▼
-0.03 (-0.23%)
As of July 24, 2026, the Syncom Formulations share price (NSE: SYNCOMF) is ₹13.09 on NSE and ₹13.10 on BSE, down 0.46% from the previous close, with shares trading between ₹12.79 and ₹13.25, and a 52-week range of ₹10.30–₹18.11.
Analyse SYNCOMF share price charts and track historical price performance.
Use the Syncom Formulations stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Syncom Formulations Market Cap
₹1,268.06 Cr.
SYNCOMF P/E Ratio (TTM)
16.65
Syncom Formulations P/B Ratio
3.06
EPS (TTM)
₹0.81
Dividend Yield
-
Debt to Equity
0.12
SYNCOMF 52 Week High
₹18.11
Syncom Formulations 52 Week Low
₹10.30
Operating Margin
16.00%
Profit Margin
16.67%
SYNCOMF Revenue (TTM)
₹150.00
EBITDA
₹37.00
Net Income
₹25.00
Total Assets
₹534.00
Total Equity
₹415.00
Syncom Formulations Share Price Chart
Screen Syncom Formulations share price with an interactive chart. Analyse SYNCOMF price trends and volatility across different timeframes.
Syncom Formulations Company Profile - Fundamental Screener
Screen Syncom Formulations company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for SYNCOMF shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE312C01025
Syncom Formulations Balance Sheet Screener
Screen SYNCOMF balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total Assets | 534 | 413 | 405 | 378 | 308 | 180 | 175 | 138 |
| Current Assets | 330 | 270 | 275 | 182 | 140 | 83 | 86 | 79 |
| Fixed Assets | 184 | 125 | 120 | 91 | 94 | 55 | 46 | 46 |
| Liabilities | ||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 15 | 12 | 10 | 9 | 8 | 8 | 6 | 6 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||
| Total Equity | 415 | 342 | 288 | 256 | 222 | 117 | 109 | 100 |
| Share Capital | 94 | 94 | 94 | 94 | 86 | 78 | 78 | 78 |
| Reserves & Surplus | 321 | 248 | 194 | 162 | 131 | 39 | 31 | 22 |
Syncom Formulations Income Statement Screener - Profit & Revenue Analysis
Screen Syncom Formulations income statement and profit fundamentals.
Analyze SYNCOMF quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Syncom Formulations share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 150 | 156 | 123 | 127 | 121 | 78 | 89 | 107 | 132 | 68 | 62 | 68 | 70 | 64 | 54 |
| Expenses | 113 | 131 | 101 | 103 | 94 | 65 | 77 | 90 | 113 | 55 | 53 | 57 | 58 | 56 | 48 |
| EBITDA | 37 | 25 | 22 | 24 | 27 | 13 | 12 | 16 | 19 | 13 | 8 | 10 | 12 | 8 | 7 |
| Operating Profit % | 16.00% | 12.00% | 14.00% | 15.00% | 18.00% | 13.00% | 12.00% | 12.00% | 12.00% | 10.00% | 11.00% | 10.00% | 11.00% | 3.00% | 7.00% |
| Depreciation | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 34 | 23 | 20 | 22 | 25 | 10 | 10 | 15 | 17 | 10 | 6 | 8 | 9 | 6 | 5 |
| Tax | 9 | 6 | 5 | 5 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 2 | 2 | 1 | 1 |
| Net Profit | 25 | 18 | 16 | 17 | 19 | 7 | 8 | 11 | 13 | 9 | 4 | 7 | 7 | 5 | 4 |
| EPS | 0.27 | 0.19 | 0.21 | 0.18 | 0.20 | 0.10 | 0.11 | 0.16 | 0.14 | 0.10 | 0.07 | 0.08 | 0.09 | 0.05 | 0.03 |
Syncom Formulations Cash Flow Screener - Liquidity Fundamentals
Screen SYNCOMF cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|
| Operating Activities | 23 | -6 | 11 | 16 | 14 | 24 | 0 |
| Investing Activities | -18 | 83 | -45 | -27 | -18 | -23 | 1 |
| Financing Activities | -68 | -15 | 35 | 8 | 5 | -2 | 1 |
| Net Cash Flow | -63 | 63 | 1 | -3 | 1 | -1 | 2 |
Syncom Formulations Shareholding Pattern Screener
See Syncom Formulations shareholding pattern with promoter, FII, and DII holdings.
Check Syncom Formulations promoter holding and ownership changes for SYNCOMF on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% |
| FII Holding | 0.21% | 0.11% | 0.41% | 0.10% | 0.26% | 0.08% | 0.09% | 0.10% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 45.15% | 45.20% | 44.83% | 45.21% | 45.04% | 44.85% | 45.08% | 45.14% |
| Other Holding | 4.06% | 4.12% | 4.19% | 4.12% | 4.13% | 4.50% | 4.27% | 4.18% |
| Shareholder Count | 431,690 | 484,529 | 471,066 | 457,364 | 442,280 | 325,761 | 376,530 | 469,242 |
Syncom Formulations Share Dividend Screener - Share Yield Analysis
Check Syncom Formulations dividend history with payout and yield data.
View Syncom Formulations dividend details including ex-dates and amounts for SYNCOMF stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.03 | 0.50% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Syncom Formulations Stock Index Membership
See which indices include Syncom Formulations stock.
Check SYNCOMF index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE INDEX BSE HC
BSE INDEX SMLCAP
Syncom Formulations Market Events Screener - Corporate Actions
Get Syncom Formulations corporate actions including splits, bonuses, and buybacks.
Check Syncom Formulations stock events that may affect SYNCOMF share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-22 | 2026-05-22 | Quarterly Result Announcement | NA | 4.93% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | 6.05% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -0.56% |
| 2025-09-29 | 2025-09-29 | Annual General Meeting | NA | -8.54% |
| 2025-08-08 | 2025-08-08 | Quarterly Result Announcement | NA | -0.72% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 6.51% |
| 2025-02-10 | 2025-02-10 | Quarterly Result Announcement | NA | 0.00% |
| 2024-11-11 | 2024-11-11 | Quarterly Result Announcement | NA | -1.49% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | -5.22% |
| 2023-09-26 | 2023-09-26 | Annual General Meeting | NA | -7.00% |
| 2022-09-09 | 2022-09-13 | Dividend | ₹ 0.03 /share | 0.00% |
Syncom Formulations Competitors Screener - Peer Comparison
Screen SYNCOMF competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 468,902 | 40.30 | 61,674 | 12.69% | 11,565 | 62.67 |
| Divis Laboratories | 194,164 | 75.03 | 10,560 | 8.73% | 2,520 | 69.61 |
| Torrent Pharmaceuticals | 189,617 | 75.44 | 13,886 | 20.34% | 2,138 | 53.08 |
| Cipla | 116,701 | 29.67 | 29,045 | 2.24% | 3,870 | 48.42 |
| Zydus Life Science | 115,958 | 22.25 | 27,658 | 17.64% | 5,026 | 59.19 |
| Lupin | 113,224 | 20.85 | 29,039 | 26.75% | 5,356 | 54.70 |
| Mankind Pharma | 105,867 | 53.09 | 14,636 | 14.85% | 1,938 | 50.34 |
| Dr Reddys Laboratories | 102,264 | 24.31 | 35,059 | 3.90% | 4,158 | 31.90 |
| Aurobindo Pharma | 90,098 | 25.44 | 33,385 | 3.21% | 3,376 | 50.49 |
| Laurus Labs | 84,137 | 92.82 | 6,868 | 22.01% | 890 | 59.60 |
Syncom Formulations Company Announcements - News Screener
Screen SYNCOMF latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-07-15 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-25 | Closure of Trading Window | - |
| 2026-05-23 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-22 | Regulation 33(3)(D) Of SEBI (LODR) Regulations 2015-Submission Of Standalone & Consolidated Audited Financial Results Along With Audit Report Statement Of Assets And Liabilities And Cash Flow For The Year Ended On 31St March 2026. | - |
| 2026-05-22 | Board Meeting Outcome for Regulation 33(3)(D) Of SEBI (LODR) Regulations 2015-Submission Of Standalone & Consolidated Audited Financial Results Along With Audit Report Statement Of Assets And Liabilities And Cash Flow For The Year Ended On 31St March 2026 | - |
| 2026-05-18 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-18 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-13 | Board Meeting Intimation for Corporate Announcement U/R 29(1)(A) Of SEBI (LODR) Regulations 2015 Regarding Intimation Of Holding Board Meeting For Consideration And Approval Of The Standalone And Consolidated Audited Financial Results As On 31St March 202 | - |
| 2026-05-04 | Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 Read With Master SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 Dated 30Th January 2026. | - |
| 2026-04-07 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-06 | Forwarding Yearly Disclosure Under Regulation 31(4) Of SEBI (SAST) Regulations 2011 By The Promoters Along With Their Person Acting In Concert(PAC) Of The Company For The Financial Year Ended On 31St March 2026. | - |
| 2026-04-03 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-12 | Regulation 33(3) Of SEBI (LODR) Regulations 2015 - Submission Of Standalone & Consolidated Unaudited Financial Results Along With Limited Review Report For The Quarter And Nine Months Ended On 31St December 2025 | - |
| 2026-02-04 | Board Meeting Intimation for Intimation Of Holding 5/2025-26 Board Meeting For Consideration And Approval Of The Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On 31St December 2025. | - |
| 2026-01-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-01-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-01-03 | Pursuant To Regulation 30 Read With Schedule III Part A Of SEBI (LODR) Regulations 2015 | - |